A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease

NCT02927314 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-alcoholic Steatohepatitis (NASH)

Interventions

DRUG: CF102
DRUG: Placebo

Sponsor

Can-Fite BioPharma